B of A Securities Upgrades Rocket Pharmaceuticals to Buy, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the price target from $4 to $10.
B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the price target from $4 to $10.